One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their impact on the brain, pointing to benefits from addiction to schizophrenia.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Instead of using the controversial body mass index, or BMI, to assess weight, an international group of scientists proposes an approach that looks at how excess body fat affects health

Councils need more support from central government to help bring down childhood obesity rates, a local authority has said. Ten years ago Gateshead Council used all the planning powers available at a local level to introduce a blanket ban on any new hot food takeaways in the area,

An international commission made the case for focusing on body fat quantity and the illnesses people experience.

New recommendations on how to define obesity would reduce the emphasis on body mass index and also take into account health problems from extra weight and other measurements.

As Tom Selleck approaches his 80th birthday on January 29, sources close to the actor reveal that he is grappling with feelings of melancholy and concerns about his health. While h

Body Mass Index, or BMI, has long been criticized as an unreliable method for measuring obesity — and now a group of experts is sharing new recommendations for how to use it.

A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for gastrointestinal and musculoskeletal issues.

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under Medicare Part D for the second round of price negotiations in 2025.